Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis - Wikidata - wikimedia - TriplyDB

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis

http://www.wikidata.org/entity/Q33640512

about

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications Early pulmonary inflammation and lung damage in children with cystic fibrosis Inhaled Antibiotics for Gram-Negative Respiratory Infections Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial.Antimicrobial treatment of non-cystic fibrosis bronchiectasis.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Challenges in the development of new therapies for bronchiectasis.New and Emerging Treatments for Cystic Fibrosis.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.2014 year in review: Cystic fibrosis.Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.Azithromycin use in patients with cystic fibrosis.Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Highlights from the 2015 North American Cystic Fibrosis Conference.An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.Clinical Trials of Novel Treatments for Cystic Fibrosis.Chronic β2AR stimulation limits CFTR activation in human airway epithelia.

P2860

Q26747065-DD303E75-216B-4700-B6B4-084A5977EBF2 Q27027040-E81C0F98-6F74-4C10-B8F4-D7ADC1DB940D Q28386160-FE140330-1DED-497A-B5F1-276694B75D21 Q33755342-21B34A56-B283-421C-8547-2541AC43BDE0 Q34596738-32419A92-81B7-437B-8116-0FA202870938 Q37734648-D31FA4BD-0B57-4E03-9110-F334AA4F3C91 Q38243206-6F518889-FB09-46F5-8B3D-A467B9B8AB33 Q38358856-795EE18B-1D6F-4126-9614-5D5B7BA1E0EC Q38387657-43B38807-E77A-4DC3-901C-CB2BF3894CD4 Q38532426-183863C4-B2FD-48CE-942A-05520EDE922D Q38579967-0CF16762-3251-4ACF-A92C-29318BFF7C9D Q38582563-B14604FA-F8B6-45D1-9984-22BBE3BE811E Q39063568-BB980657-07A1-4589-9156-92B1A924F35F Q40859615-E5783E8A-1CB6-4DD7-80E8-DF7BEFF1FA1F Q41428470-4281993C-78BA-496E-9679-A5A62B296D35 Q43538692-D873ECD9-900D-4416-80F3-CD30940ABF2A Q45294315-AF65911C-AA3B-4CCE-98DD-C7B2DF39CBF9 Q47964873-ED363941-88D4-449F-BC76-41649DDFF908 Q51556179-DF2349C9-8AD6-410D-9416-CAAA82F52588 Q51749305-C519D424-96A7-4512-8C5D-5D3527703686

P2860

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis

http://www.wikidata.org/entity/Q33640512

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@ast

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@en

type

label

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@ast

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@en

prefLabel

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@ast

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@en

P1433

Q33640512-A974DD1B-1895-4383-BB42-633BCE3A1407

P1476

Q33640512-2A81CD42-1C0D-474D-9B82-DB9FA91F5655

P2093

Q33640512-0204484F-CAD8-424F-A46F-AA8EC479D4B2

Q33640512-67A9FC62-0C71-4A1C-A8B2-95B5DB8C85A0

Q33640512-84D53705-C89B-4B35-9779-00F42301B5B5

Q33640512-C27434AE-5A20-4BD1-AD9A-B67266FE2075

Q33640512-C9B6F364-402D-41A4-87C3-5D9B865FD51C

Q33640512-D64C160D-7B3C-49B8-8426-10E4A96EA777

Q33640512-D9A632EA-2E25-49F9-B739-1CE946E68E7D

Q33640512-EB361ED8-2B38-4C76-9F5E-7822EF65DB68

Q33640512-F113E9FD-7C13-4FFB-B65D-857D6C8C1C6F

P2860

Q33640512-140DB8B0-BB7D-4CC5-A1AF-902EB29A8145

Q33640512-1C8636F5-F0C1-4A41-BCE2-CB6F55BB1CD7

Q33640512-276A8F55-2144-49D7-9FFF-E5DD16E5A59D

Q33640512-44095FD4-1A30-4AC4-B5E4-FF49AB2D31E6

Q33640512-52175C3B-B9ED-443B-9B6C-FAC92A1E5757

Q33640512-5BE6143A-2FF5-469A-B6EE-5D3951A09398

Q33640512-66CDC1D4-581E-4225-81B3-AE5A61891B6A

Q33640512-6F48196B-F654-4092-98FD-4DC7E1337E91

Q33640512-77FB0CBC-C5A8-4A30-BF0B-031A850E0EC1

Q33640512-7A9570C5-FF42-429A-A21A-B913166AB215

P304

Q33640512-BCDEBE88-A636-4F88-B535-38A409AF854E

P31

Q33640512-07F5A3C2-6A03-469D-9FBC-496F0CF5AD5A

P356

Q33640512-E09449D2-B5B7-4811-B036-582A5E6A13E3

P433

Q33640512-4938BD54-EA54-4E1C-A02B-6B35FDABE482

P478

Q33640512-272D20BB-1BE9-465F-A218-9AF4FAFC1553

P577

Q33640512-C468F135-AA44-4C0A-93EB-F060921468C6

P5875

Q33640512-0E6F6654-E33D-4E7F-B633-4221FD0158BB

P698

Q33640512-ACA4FB12-51ED-46FB-8D4E-477D317AFDB1

P921

Q33640512-6FA08953-2501-47EC-85AC-319A3A771CC8

Q33640512-971A877E-FA62-4EF1-A342-E625D7BBADDE

Q33640512-9C732992-9EAC-4982-B5FE-B3419591A780

P932

Q33640512-A9E523E8-1705-4E88-B965-D9579B89E23B

P356

ANNALSATS.201310-352OC

P1433

Proceedings of the American Thoracic Society

P1476

Azithromycin may antagonize in ...... aeruginosa in cystic fibrosis

@en

P2093

Anna V Forssén

http://www.w3.org/2001/XMLSchema#string

David P Nichols

http://www.w3.org/2001/XMLSchema#string

James F Chmiel

http://www.w3.org/2001/XMLSchema#string

Jennifer L Taylor-Cousar

http://www.w3.org/2001/XMLSchema#string

Jerry A Nick

http://www.w3.org/2001/XMLSchema#string

Lisa Saiman

http://www.w3.org/2001/XMLSchema#string

Milene T Saavedra

http://www.w3.org/2001/XMLSchema#string

Samuel M Moskowitz

http://www.w3.org/2001/XMLSchema#string

Sun Ho Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Quantification of biofilm structures by the novel computer program comstat

Interaction revisited: the difference between two estimates

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses

P304

342-350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1513/ANNALSATS.201310-352OC

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259984366

http://www.w3.org/2001/XMLSchema#string

P698

24476418

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

P932

4028742

http://www.w3.org/2001/XMLSchema#string